Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial

Dose-Escalating (50–500 mg) Gluten Administration Leads to Detectable Gluten-Immunogenic-Peptides in Urine of Patients with Coeliac Disease Which Is Unrelated to Symptoms, a Placebo Controlled Trial

Background: To determine the applicability and sensitivity of a urine self-test to detect gluten-immunogenic-peptides (GIP) in daily-life for patients with coeliac disease and correlate the test results with reported symptoms. Methods: We performed a prospective double-blinded placebo-controlled stu...

Full description

Bibliographic Details
Main Authors: Jordy P. W. Burger, Ellen G. van Lochem, Elisabeth A. Roovers, Joost P. H. Drenth, Peter J. Wahab
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Nutrients
Subjects:
coeliac disease
gluten immunogenic peptides
gluten excretion urine
gluten-free diet monitoring
Online Access:https://www.mdpi.com/2072-6643/14/9/1771

Similar Items

Similar Items